Jessica Merrill

Also from @FT pharma summit https://t.co/oqLwNMnUqt

FTC Deputy director of the Bureau of Competition Rahul Rao talked about the agency's views on pharma consolidation and actions some in the industry have viewed as controversial @ the FT pharma summit. https://t.co/FVaN1Frkhc

Rosier macro-economic outlook and excitement over new breakthroughs was juxtaposed against the challenge of paying for them and the dawning realization that the US health care system is pushing back against the industry in very real and tangible ways.https://t.co/wZ7byWywIZ

Visited $PFE’s new NYC headquarters in Hudson Yards this am. What’s on the bookshelves (along with a fave @emmastraub Modern Lovers) Thanks Pfizer for having me. https://t.co/6QjZb1QHFY

Regeneron CEO Takes Industry Counterview On FTC News: “I’m Glad They’re Looking Into This” :: Scrip https://t.co/Bmev5S6rli

“I’m glad that the FTC is looking at this,” $ REGN CEO Len Schleifer says at #ftpharma summit. He points out Regeneron has pending litigation with $AMGN over rebate practices related to PCSK9s.

FTC is blocking $AMGN acquisition of $HZNP …over a history of bundling rebates, long a common practice among big pharma manufacturers. This, despite Amgen agreeing not to bundle the Horizon products.

$BMY has changed dramatically since Caforio took the helm in 2015, transitioning away from antivirals while growing into an oncology/CV leader with $46.2bn in 2022 revenues, versus $16.5bn in 2015, driven by the growth of Eliquis/Opdivo, and Celgene. https://t.co/DjeDnne7FN

$AMGN wins appeals court decision on #Otezla, protecting the oral psoriasis drug from generic competition until 2028. It was approved in 2014.

PhRMA's incoming board chair and $NVS CEO Vasant Narasimhan talks to @PharmaPinkSheet about efforts to improve Medicare drug price negotiation policies stemming from IRA. https://t.co/YA6EwK5MLj

$VRTX's R&D strategy is centered on being therapeutically agnostic; the firm will soon have to put that strategy to the commercial test. COO Stuart Arbuckle & CSO David Altshuler talked to Scrip. https://t.co/JbFrBSnrxf

Aiming to solve some big commercial challenges in the US, $NVS has put in place a new vertical commercial structure, reduced its therapeutic area focus to emphasize broader market issues instead, and recruited marketing experts from outside industry. https://t.co/c1X7g0SxdL

It was great to be back at #JPM23; I didn't miss the bottlenecks in the Westin but did miss the spontaneity that sometimes came out of the breakout rooms. The atmosphere felt a bit tense, but the North star remains innovation. https://t.co/TV3fkwEb6N

The way my #JPM23 is going in a photo. https://t.co/gSZSBIMHmS

RT @SarahKarlin: A look at the drugs FDA declined to approve in 2022: https://t.co/omhP0FOk2U

Where do we catch the boat to the Westin? #JPM23

After covering disappointment after disappointment in Alzheimer's for two decades, and then Aduhelm, it's hard not feel skepticism but the approval of Leqembi is still a milestone. https://t.co/JrkasxkFQg